Clinical Trials Logo

SCCHN clinical trials

View clinical trials related to SCCHN.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04107103 Completed - SCCHN Clinical Trials

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma

NivoPlus
Start date: March 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects the combination of Nivolumab and Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness of this treatment will be studied.

NCT ID: NCT02573259 Completed - MELANOMA Clinical Trials

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Start date: February 10, 2016
Phase: Phase 1
Study type: Interventional

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.